1. CLEARSUNPredictive value of drug elimination gene polymorphisms on clearance and dose adjustment of sunitinib (Sutent, SU11248) in patients with cancer Sponsor: Westmead Medical Oncology (SWAHS) Phase 2 Any patients receiving Sutent. Patients have PK samples taken as well as Sestamibi liver scan, midazolam clearance and blood sample for drug elminination gene polymorphisms Eligibility: Open protocol (PDF) Status: Closed
Contact: Dr Bavanthi Balakrishnar
2. TADE
A Multi-Centre Study of Tamoxifen Dose Escalation Study in Breast Cancer Patients with CYP2D6 Polymorphisms
Sponsor: Westmead Medical Oncology (SWAHS) Phase 2 For any patient taking tamoxifen for breast cancer. The study will determine whether the level of endoxifen (the active metabolite of tamoxifen) can be increased by tamoxifen dose escalation in those patients found to have low endoxifen blood level. The genotype of the CYP2D6 metabolising enzyme will also be measured and correlated with increase in endoxifen level.
Eligibility: Go to ClinicalTrial.gov
Status: Recruiting Contact: Dr Bavanthi Balakrishnar |